Form 4: Crinetics Pharmaceuticals Officer Sells Shares Under 10b5-1 Trading Plan

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on June 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on June 25, 2024.
• The sale was executed automatically under a Rule 10b5-1 trading plan previously adopted by Mr. Betz.
• The shares were sold at a volume weighted average price of $45.37 per share, with individual sales prices ranging from $45.16 to $46.06.
• Following the transaction, Mr. Betz still beneficially owns 80,643 shares of Crinetics Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the officer's outlook on the company.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. Investors often monitor these filings for insights into management's sentiment, although sales under 10b5-1 plans are less indicative of sentiment than discretionary trades.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates